Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6422MR)

This product GTTS-WQ6422MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6422MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5900MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ3143MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ13611MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ10834MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ8441MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ7942MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ3743MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW